Drug Profile


Alternative Names: Amdray; PSC 833; SDZ PSC 833

Latest Information Update: 12 Sep 2001

Price : $50

At a glance

  • Originator Novartis
  • Class Antineoplastics
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Cancer; Multiple myeloma; Ovarian cancer; Renal cancer

Most Recent Events

  • 12 Sep 2001 A phase I/II trial has been added to the pharmacokinetics and Cancer therapeutic trials sections
  • 19 Apr 2001 Discontinued-III for Acute myeloid leukaemia in European Union (IV-infusion)
  • 19 Apr 2001 Discontinued-III for Acute myeloid leukaemia in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top